As Bausch Health (BHC) attempts to swallow up bankrupt Synergy Pharmaceuticals (SGYP), Seeking Alpha blogger Biotech Spectator (BS) says Synergy’s beloved Irritable Bowel …
Bausch Health Companies (BHC) announced today it will acquire some assets of Synergy Pharmaceuticals, which is being called the “stalking horse” agreement – …
As Synergy Pharmaceuticals (SGYP) trudges its way through economic difficulty, the company has more unfortunate news up ahead — BTIG’s analyst Tim Chiang …
Synergy Pharmaceuticals (SGYP) is considering filing for bankruptcy protection as it faces a large debt repayment. Shares of Synergy plunged as much as …
Ladenburg analyst Kevin Degeeter was out pounding the table on shares of Synergy Pharmaceuticals (NASDAQ:SGYP), initiating a Buy rating and price target of $3.00, which …
As Synergy Pharmaceuticals (NASDAQ:SGYP) revealed new clinical data during the Digestive Disease Week (DDW) conference, H.C.
Oppenheimer’s Christopher Liu and Cantor’s William Tanner see potential in Synergy’s Trulance, even if its momentum is not full steam ahead just yet.
BTIG’s Tim Chiang is out with a positive research note, singing the praises of SGYP and 1Q earnings that put Trulance’s potential in the limelight.
Canaccord’s John Newman is out with bullish praise for Synergy, even if investors are less-than-enthused on back of Q1 results.
Synergy Pharmaceuticals (NASDAQ:SGYP) saw its shares crater 10% in after-hours trading Thursday, after the drug maker revealed disappointing first-quarter earnings results. To put …